Cohance Life Q1 FY27 Earnings Call — Analysis (NSE: COHANCE)

Q1FY27 was the lowest quarter ever; management expects sequential improvement from Q2 and a return to YoY growth from H2, driven by scheduled deliveries, restocking orders, and improving utilization.

11 Aug 2026 · Analysis by Alpha Inflection

Result quality: poor — Slipped to loss. Management sentiment: neutral.

The take

Q1FY27 Consolidated Revenue ₹422.3 Cr ( -23% YoY ) . New guidance — FY27 consolidated ebitda margin closer to previous year margin percentage . New story: Trough quarter, recovery ahead .

Results

Consolidated revenue ₹422.3 Cr, -23% YoY; adj. EBITDA ₹9.2 Cr (2.2% margin); standalone revenue ₹359.9 Cr with 9.2% EBITDA margin; Sapala grew 2.5x YoY to ₹27.4 Cr, offset by NJBio loss of ₹32.8 Cr.

Financial highlights

Guidance

Consolidated FY27 margins expected to approach prior-year levels; sequential recovery begins Q2, YoY growth from H2; Specialty Chem pivot to innovation aims for double-digit growth from FY28.

What management committed to

• Consolidated revenue will improve sequentially in Q2FY27 and return to year-on-year growth from the second half of FY27. — FY27
• Customized ADC payload order will be delivered in Q2FY27. — Q2FY27
• [API+ business] will file seven new API filings in FY27. — 7, FY27
• [Formulations business] will launch around 10 products in FY27, including two in Q2FY27. — ~10, FY27
• [Specialty Chemicals AgChem CDMO] will qualify approximately two new products each year, combining opportunities with [existing anchor customer] and new customers across Europe and Japan, starting FY27. — approximately two, FY27
• Cohance will achieve full ownership of Sapala by FY30. — FY30
• [Sapala/oligonucleotide business] revenue has a solid chance of almost doubling in 3 to 4 years from Q1FY27. — almost doubling, FY30
• Consolidated EBITDA margin for FY27 will be closer to previous year margin percentage. — closer to previous year margin percentage, FY27
• [Restocking order for a commercial molecule] will contribute meaningful revenue in Q4FY27 and FY28. — FY28
• Commercial flow reactor at Jaggayyapet site will be ready by Q2FY27. — Q2FY27
• [Specialty Chemicals] portfolio can support a sustained trajectory of double-digit growth from FY28 onwards, subject to customer qualification and regulatory timelines. — double-digit growth, FY28

Key themes

Trough quarter, pipeline conversion, and nucleic acid integration

How the narrative shifted

• Trough quarter, recovery ahead: Management positions Q1FY27 as the deliberate lowest point, with scheduled deliveries, restocking, and new program execution driving sequential and year-on-year improvement.
• CDMO pipeline conversion broadening: Two new molecules entering commercial supply, restocking order secured, and a growing late-stage funnel are presented as evidence of a turning point in CDMO revenue momentum.
• Nucleic acid platform integration: Aligning Sapala and Cohance capabilities into an integrated nucleic acid offering, with clear leadership and a defined path to full ownership by FY30, signals commitment to a high-growth vertical.
• Specialty chemicals innovator transition: Shifting from Chinese-generic-facing agrochemicals to innovator-led CDMO engagements, with qualification campaigns and registration milestones in FY27 as proof points.
• API+ resilience as earnings bedrock: The API segment performed ahead of expectations with a robust order book and niche CNS/controlled-substance portfolio; positioned as predictable, stable growth that anchors the broader CDMO platform.
• NJBio cost drag and biotech funding watch: NJBio's US-based operations are a significant drag on consolidated profitability, with recovery contingent on FTE renewals and broader biotech funding environment improvement.
• Regulatory milestones and compliance reinforcement: Multiple customer audits completed without critical findings, though USFDA Pashamylaram 483 introduces a watch item; management frames compliance as a system-strengthening priority.
• Capital allocation tied to innovation partnerships: Capital will be deployed where Cohance has scientific differentiation and innovation-partnered programs, not along segment lines; this is a value-chain-upgrading rubric.

Operational commentary

• Secured significant restocking order for a commercial molecule, providing delivery visibility across Q4FY27 and FY28.
• Two molecules entered commercial supply with six intermediates scheduled for delivery in Q2-Q3FY27.
• Customized ADC payload order on schedule for delivery in Q2FY27.
• Sapala commenced oligonucleotide shipments for an orphan drug candidate, driving 2.5x YoY revenue growth, and initiated integrated nucleic acid offerings with a defined path to full ownership of Sapala by FY30.
• Specialty Chemicals AgChem active ingredient entered registration process; two Japanese innovator qualification campaigns scheduled in FY27, targeting ~2 new product qualifications per year.
• API+ business secured two CEP approvals, filed two Korean DMFs, targeting seven new API filings in FY27; commercial flow reactor at Jaggayyapet expected by Q2FY27; 11 customer audits completed.
• Multiple customer audits across CDMO and API manufacturing sites completed without critical findings; CAPA review for a strategic customer progressing with potential new awards.
• NJ Bio operationalized additional GMP lab at Princeton; released another GMP ADC batch; continued engagement across ADC conjugation, oligonucleotides, and AOC programs.
• Formulations finalized supply agreement covering selected Middle Eastern markets; scheduled two product launches in Q2FY27 and ~10 in FY27.
• Nacharam remediation on track, product supplies resumed; USFDA Pashamylaram inspection concluded with Form 483 containing 5 non-data-integrity observations, response in process.
• RFQ pipeline strengthening with many Phase 3 KSM inquiries from large pharma and Western CDMOs; late-stage opportunity funnel expanded.
• Progressing organizational integration and evaluating targeted capacity additions across small molecules, ADCs, API+, and specialty chemicals.

Analyst Q&A

• Q. What are the growth ranges for each business segment over 2-3 years and capital allocation philosophy?

  Umang Vohra detailed each segment: oligonucleotides could double in 3-4 years; ADC pipeline significant but NJBio costs need to match revenue; small molecule CDMO conversions picking up, H2FY27 should be strong; API+ is bedrock with steady growth, still 30-40% of potential; AgChem/P Chem moving up value chain with innovators. Capital allocation prioritizes innovation-partnered programs across all segments, not just CDMO.

• Q. Macro environment for CDMO and impact on RFQs and order wins for Indian firms, including Cohance.

  Yann D’Herve cited geopolitical diversification, US-India supply alignment, increased Phase 3 and commercial RFQs, but noted clients already have 1-2 sources so conversion takes time. Cohance is benefiting from these trends.

• Q. What gives Cohance differentiation in small molecule CDMO given intense competition?

  Umang Vohra emphasized deepening existing anchor relationships (7-10 year trust cycles), building scientific expertise that makes Cohance a partner customers call, and competing on capability and relationship, not just cost. He acknowledged some peers moved faster and past leadership churn didn't help, but confidence in widening key accounts.

• Q. Does Cohance still retain the $1 billion sales target for FY30?

  Umang Vohra said he does not have a firm enough answer yet, the target is an aspiration and they may be a little bit away from it over the next 3-4 years; he will provide more granularity by December.

• Q. Segment revenue expectations over the next 2-3 quarters and details on molecules.

  Umang Vohra indicated they had already answered a similar question earlier in the call and offered to share that response separately, declining to provide additional specifics on molecules on the call.

• Q. What is the outlook for other expenses, which have remained elevated since the merger?

  Himanshu Agarwal stated there are no merger-related expenses in this quarter, these are regular administrative expenses and can be assumed to continue at similar levels.

View source

Research and educational content only. Not investment advice.